{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:30:15Z","timestamp":1761921015855,"version":"3.37.3"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T00:00:00Z","timestamp":1651104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T00:00:00Z","timestamp":1651104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s00415-022-11134-7","type":"journal-article","created":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T07:02:26Z","timestamp":1651129346000},"page":"4895-4908","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Objectively assessed physiological, physical, and cognitive function along with patient-reported outcomes during the first 2 years of Alemtuzumab treatment in multiple sclerosis: a prospective observational study"],"prefix":"10.1007","volume":"269","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3233-0429","authenticated-orcid":false,"given":"Lars G.","family":"Hvid","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4877-5193","authenticated-orcid":false,"given":"Egon","family":"Stenager","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4132-2789","authenticated-orcid":false,"given":"Ulrik","family":"Dalgas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,28]]},"reference":[{"issue":"5","key":"11134_CR1","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1474-4422(18)30499-X","volume":"18","author":"GBD_MS_Collaborators","year":"2019","unstructured":"GBD_MS_Collaborators (2019) Global, regional, and national burden of neurological disorders, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 18(5):459\u2013480","journal-title":"Lancet Neurol"},{"issue":"2","key":"11134_CR2","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1056\/NEJMra1401483","volume":"378","author":"DS Reich","year":"2018","unstructured":"Reich DS, Lucchinetti CF, Calabresi PA (2018) Multiple sclerosis. N Engl J Med 378(2):169\u2013180","journal-title":"N Engl J Med"},{"issue":"2","key":"11134_CR3","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s10072-015-2400-1","volume":"37","author":"T Vollmer","year":"2016","unstructured":"Vollmer T et al (2016) Relationship between brain volume loss and cognitive outcomes among patients with multiple sclerosis: a systematic literature review. Neurol Sci 37(2):165\u2013179","journal-title":"Neurol Sci"},{"key":"11134_CR4","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3389\/fneur.2017.00433","volume":"8","author":"MA Rocca","year":"2017","unstructured":"Rocca MA, Comi G, Filippi M (2017) The role of T1-weighted derived measures of neurodegeneration for assessing disability progression in multiple sclerosis. Front Neurol 8:433","journal-title":"Front Neurol"},{"issue":"2","key":"11134_CR5","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/ene.12715","volume":"23","author":"V Planche","year":"2016","unstructured":"Planche V et al (2016) Cognitive impairment in a population-based study of patients with multiple sclerosis: differences between late relapsing-remitting, secondary progressive and primary progressive multiple sclerosis. Eur J Neurol 23(2):282\u2013289","journal-title":"Eur J Neurol"},{"issue":"9","key":"11134_CR6","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1177\/1352458516674367","volume":"23","author":"L Ruano","year":"2017","unstructured":"Ruano L et al (2017) Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes. Mult Scler 23(9):1258\u20131267","journal-title":"Mult Scler"},{"issue":"3","key":"11134_CR7","doi-asserted-by":"publisher","first-page":"189","DOI":"10.2165\/11591150-000000000-00000","volume":"4","author":"NG Larocca","year":"2011","unstructured":"Larocca NG (2011) Impact of walking impairment in multiple sclerosis: perspectives of patients and care partners. Patient 4(3):189\u2013201","journal-title":"Patient"},{"issue":"4","key":"11134_CR8","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1177\/1545968320907074","volume":"34","author":"LG Hvid","year":"2020","unstructured":"Hvid LG et al (2020) Accelerated trajectories of walking capacity across the adult life span in persons with multiple sclerosis: an underrecognized challenge. Neurorehabil Neural Repair 34(4):360\u2013369","journal-title":"Neurorehabil Neural Repair"},{"issue":"1","key":"11134_CR9","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/bpa.12220","volume":"25","author":"GC DeLuca","year":"2015","unstructured":"DeLuca GC et al (2015) Cognitive impairment in multiple sclerosis: clinical, radiologic and pathologic insights. Brain Pathol 25(1):79\u201398","journal-title":"Brain Pathol"},{"issue":"3","key":"11134_CR10","doi-asserted-by":"publisher","first-page":"146","DOI":"10.7224\/1537-2073.2012-053","volume":"15","author":"I Kister","year":"2013","unstructured":"Kister I et al (2013) Natural history of multiple sclerosis symptoms. Int J MS Care 15(3):146\u2013158","journal-title":"Int J MS Care"},{"key":"11134_CR11","first-page":"135245852093623","volume":"27","author":"C Thrue","year":"2020","unstructured":"Thrue C et al (2020) Time matters: early-phase multiple sclerosis is accompanied by considerable impairments across multiple domains. Mult Scler 27:1352458520936231","journal-title":"Mult Scler"},{"issue":"4","key":"11134_CR12","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1097\/NPT.0b013e31823801f4","volume":"35","author":"A Kalron","year":"2011","unstructured":"Kalron A, Achiron A, Dvir Z (2011) Muscular and gait abnormalities in persons with early onset multiple sclerosis. J Neurol Phys Ther 35(4):164\u2013169","journal-title":"J Neurol Phys Ther"},{"issue":"Suppl 1","key":"11134_CR13","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1016\/j.msard.2016.07.003","volume":"9","author":"G Giovannoni","year":"2016","unstructured":"Giovannoni G et al (2016) Brain health: time matters in multiple sclerosis. Mult Scler Relat Disord 9(Suppl 1):S5\u2013S48","journal-title":"Mult Scler Relat Disord"},{"issue":"3","key":"11134_CR14","first-page":"205521731772830","volume":"3","author":"R Green","year":"2017","unstructured":"Green R et al (2017) Which symptoms contribute the most to patients\u2019 perception of health in multiple sclerosis? Mult Scler J Exp Transl Clin 3(3):2055217317728301","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"3","key":"11134_CR15","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/ane.12881","volume":"137","author":"C Heesen","year":"2018","unstructured":"Heesen C et al (2018) Perceptions on the value of bodily functions in multiple sclerosis. Acta Neurol Scand 137(3):356\u2013362","journal-title":"Acta Neurol Scand"},{"issue":"8","key":"11134_CR16","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1001\/jama.2020.26858","volume":"325","author":"MP McGinley","year":"2021","unstructured":"McGinley MP, Goldschmidt CH, Rae-Grant AD (2021) Diagnosis and treatment of multiple sclerosis: a review. JAMA 325(8):765\u2013779","journal-title":"JAMA"},{"issue":"Suppl 1","key":"11134_CR17","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/ene.12883","volume":"23","author":"\u00d8 Torkildsen","year":"2016","unstructured":"Torkildsen \u00d8, Myhr KM, B\u00f8 L (2016) Disease-modifying treatments for multiple sclerosis - a review of approved medications. Eur J Neurol 23(Suppl 1):18\u201327","journal-title":"Eur J Neurol"},{"issue":"1","key":"11134_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40893-017-0033-3","volume":"3","author":"A Favaretto","year":"2018","unstructured":"Favaretto A et al (2018) Effects of disease modifying therapies on brain and grey matter atrophy in relapsing remitting multiple sclerosis. Mult Scler Demyelinating Disord 3(1):1","journal-title":"Mult Scler Demyelinating Disord"},{"key":"11134_CR19","doi-asserted-by":"publisher","first-page":"175628642110195","DOI":"10.1177\/17562864211019574","volume":"14","author":"P Iaffaldano","year":"2021","unstructured":"Iaffaldano P et al (2021) Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies. Ther Adv Neurol Disord 14:17562864211019574","journal-title":"Ther Adv Neurol Disord"},{"issue":"22","key":"11134_CR20","doi-asserted-by":"publisher","first-page":"e2373","DOI":"10.1212\/WNL.0000000000009522","volume":"94","author":"NC Landmeyer","year":"2020","unstructured":"Landmeyer NC et al (2020) Disease-modifying treatments and cognition in relapsing-remitting multiple sclerosis: a meta-analysis. Neurology 94(22):e2373\u2013e2383","journal-title":"Neurology"},{"issue":"11","key":"11134_CR21","doi-asserted-by":"publisher","first-page":"3235","DOI":"10.1007\/s10072-020-04367-9","volume":"41","author":"R Lanzillo","year":"2020","unstructured":"Lanzillo R et al (2020) A snapshot on patient-reported outcome measures of people with multiple sclerosis on first-line therapies in a real world setting. Neurol Sci 41(11):3235\u20133241","journal-title":"Neurol Sci"},{"issue":"4","key":"11134_CR22","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1007\/s13311-017-0571-6","volume":"14","author":"CJ Nowinski","year":"2017","unstructured":"Nowinski CJ, Miller DM, Cella D (2017) Evolution of patient-reported outcomes and their role in multiple sclerosis clinical trials. Neurotherapeutics 14(4):934\u2013944","journal-title":"Neurotherapeutics"},{"issue":"11","key":"11134_CR23","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s11910-019-1002-3","volume":"19","author":"U Dalgas","year":"2019","unstructured":"Dalgas U et al (2019) Exercise as medicine in multiple sclerosis-time for a paradigm shift: preventive, symptomatic, and disease-modifying aspects and perspectives. Curr Neurol Neurosci Rep 19(11):88","journal-title":"Curr Neurol Neurosci Rep"},{"unstructured":"Rooney S et al (2019) Physical activity is associated with neuromuscular and physical function in patients with multiple sclerosis independent of disease severity. Disabil Rehabil, p 1\u20138","key":"11134_CR24"},{"issue":"4","key":"11134_CR25","doi-asserted-by":"publisher","first-page":"137","DOI":"10.7224\/1537-2073-7.4.137","volume":"7","author":"EMM Snook","year":"2005","unstructured":"Snook EMM, Mojtahedi C et al (2005) Physical activity and body composition among ambulatory individuals with multiple sclerosis. Intern J MS Care 7(4):137\u2013142","journal-title":"Intern J MS Care"},{"key":"11134_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.101864","volume":"38","author":"BT Cleland","year":"2020","unstructured":"Cleland BT et al (2020) Determinants of low bone mineral density in people with multiple sclerosis: role of physical activity. Mult Scler Relat Disord 38:101864","journal-title":"Mult Scler Relat Disord"},{"issue":"11","key":"11134_CR27","doi-asserted-by":"publisher","first-page":"3332","DOI":"10.1002\/eji.200535075","volume":"35","author":"AL Cox","year":"2005","unstructured":"Cox AL et al (2005) Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur J Immunol 35(11):3332\u20133342","journal-title":"Eur J Immunol"},{"issue":"7","key":"11134_CR28","first-page":"2052","volume":"119","author":"JL Jones","year":"2009","unstructured":"Jones JL et al (2009) IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest 119(7):2052\u20132061","journal-title":"J Clin Invest"},{"issue":"1","key":"11134_CR29","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10875-009-9327-3","volume":"30","author":"SA Thompson","year":"2010","unstructured":"Thompson SA et al (2010) B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis. J Clin Immunol 30(1):99\u2013105","journal-title":"J Clin Immunol"},{"issue":"9856","key":"11134_CR30","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","volume":"380","author":"AJ Coles","year":"2012","unstructured":"Coles AJ et al (2012) Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 380(9856):1829\u20131839","journal-title":"Lancet"},{"issue":"19","key":"11134_CR31","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1212\/WNL.0000000000003319","volume":"87","author":"G Giovannoni","year":"2016","unstructured":"Giovannoni G et al (2016) Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients. Neurology 87(19):1985\u20131992","journal-title":"Neurology"},{"issue":"10","key":"11134_CR32","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1177\/1756285617722706","volume":"10","author":"T Ziemssen","year":"2017","unstructured":"Ziemssen T, Thomas K (2017) Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world. Ther Adv Neurol Disord 10(10):343\u2013359","journal-title":"Ther Adv Neurol Disord"},{"issue":"12","key":"11134_CR33","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.1007\/s00415-019-09395-w","volume":"267","author":"H Li","year":"2020","unstructured":"Li H et al (2020) Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis. J Neurol 267(12):3489\u20133498","journal-title":"J Neurol"},{"issue":"6","key":"11134_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102826","volume":"20","author":"Z Liu","year":"2021","unstructured":"Liu Z et al (2021) Disease modifying therapies in relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis. Autoimmun Rev 20(6):102826","journal-title":"Autoimmun Rev"},{"key":"11134_CR35","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2147\/JIR.S38079","volume":"7","author":"O Fernandez","year":"2014","unstructured":"Fernandez O (2014) Alemtuzumab in the treatment of multiple sclerosis. J Inflamm Res 7:19\u201327","journal-title":"J Inflamm Res"},{"key":"11134_CR36","doi-asserted-by":"publisher","first-page":"730","DOI":"10.3389\/fneur.2017.00730","volume":"8","author":"E Riepl","year":"2017","unstructured":"Riepl E et al (2017) Alemtuzumab improves cognitive processing speed in active multiple sclerosis-a longitudinal observational study. Front Neurol 8:730","journal-title":"Front Neurol"},{"issue":"10","key":"11134_CR37","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1177\/1352458516677589","volume":"23","author":"R Arroyo Gonz\u00e1lez","year":"2017","unstructured":"Arroyo Gonz\u00e1lez R et al (2017) Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis. Mult Scler 23(10):1367\u20131376","journal-title":"Mult Scler"},{"key":"11134_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.exger.2020.111025","volume":"139","author":"PS Sieljacks","year":"2020","unstructured":"Sieljacks PS et al (2020) Lower extremity muscle strength across the adult lifespan in multiple sclerosis: implications for walking and stair climbing capacity. Exp Gerontol 139:111025","journal-title":"Exp Gerontol"},{"issue":"5","key":"11134_CR39","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1177\/1352458514549402","volume":"21","author":"T Kjolhede","year":"2015","unstructured":"Kjolhede T et al (2015) Neuromuscular adaptations to long-term progressive resistance training translates to improved functional capacity for people with multiple sclerosis and is maintained at follow-up. Mult Scler 21(5):599\u2013611","journal-title":"Mult Scler"},{"issue":"10","key":"11134_CR40","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1016\/j.clinph.2009.10.040","volume":"121","author":"D Farina","year":"2010","unstructured":"Farina D et al (2010) Decoding the neural drive to muscles from the surface electromyogram. Clin Neurophysiol 121(10):1616\u20131623","journal-title":"Clin Neurophysiol"},{"issue":"9","key":"11134_CR41","doi-asserted-by":"publisher","first-page":"272","DOI":"10.3390\/jcm7090272","volume":"7","author":"M Langeskov-Christensen","year":"2018","unstructured":"Langeskov-Christensen M et al (2018) Aerobic capacity is not associated with most cognitive domains in patients with multiple sclerosis\u2014a cross-sectional investigation. J Clin Med 7(9):272","journal-title":"J Clin Med"},{"issue":"5","key":"11134_CR42","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1249\/00005768-198205000-00012","volume":"14","author":"GA Borg","year":"1982","unstructured":"Borg GA (1982) Psychophysical bases of perceived exertion. Med Sci Sports Exerc 14(5):377\u2013381","journal-title":"Med Sci Sports Exerc"},{"issue":"3","key":"11134_CR43","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1177\/1352458511420598","volume":"18","author":"D Gijbels","year":"2012","unstructured":"Gijbels D et al (2012) Which walking capacity tests to use in multiple sclerosis? A multicentre study providing the basis for a core set. Mult Scler 18(3):364\u2013371","journal-title":"Mult Scler"},{"key":"11134_CR44","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.msard.2019.01.034","volume":"29","author":"J Callesen","year":"2019","unstructured":"Callesen J et al (2019) How much does balance and muscle strength impact walking in persons with multiple sclerosis? A cross-sectional study. Mult Scler Relat Disord 29:137\u2013144","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"11134_CR45","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/j.1532-5415.1991.tb01616.x","volume":"39","author":"D Podsiadlo","year":"1991","unstructured":"Podsiadlo D, Richardson S (1991) The timed \u201cUp & Go\u201d: a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc 39(2):142\u2013148","journal-title":"J Am Geriatr Soc"},{"issue":"26","key":"11134_CR46","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.3109\/09638288.2012.683479","volume":"34","author":"AB Moller","year":"2012","unstructured":"Moller AB et al (2012) Validity and variability of the 5-repetition sit-to-stand test in patients with multiple sclerosis. Disabil Rehabil 34(26):2251\u20132258","journal-title":"Disabil Rehabil"},{"key":"11134_CR47","volume-title":"A manual for the brief repeatable battery of neuropsychological tests in multiple sclerosis","author":"S Rao","year":"1990","unstructured":"Rao S (1990) A manual for the brief repeatable battery of neuropsychological tests in multiple sclerosis. Medical College of Wisconsin, Milwaukee"},{"key":"11134_CR48","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.msard.2016.09.009","volume":"10","author":"M Roar","year":"2016","unstructured":"Roar M, Illes Z, Sejbaek T (2016) Practice effect in Symbol Digit Modalities Test in multiple sclerosis patients treated with natalizumab. Mult Scler Relat Disord 10:116\u2013122","journal-title":"Mult Scler Relat Disord"},{"issue":"Pt 5","key":"11134_CR49","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1093\/brain\/124.5.962","volume":"124","author":"J Hobart","year":"2001","unstructured":"Hobart J et al (2001) The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. Brain 124(Pt 5):962\u2013973","journal-title":"Brain"},{"issue":"1","key":"11134_CR50","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1212\/WNL.60.1.31","volume":"60","author":"JC Hobart","year":"2003","unstructured":"Hobart JC et al (2003) Measuring the impact of MS on walking ability: the 12-Item MS Walking Scale (MSWS-12). Neurology 60(1):31\u201336","journal-title":"Neurology"},{"issue":"Suppl 1","key":"11134_CR51","doi-asserted-by":"publisher","first-page":"S79","DOI":"10.1093\/clinids\/18.Supplement_1.S79","volume":"18","author":"JD Fisk","year":"1994","unstructured":"Fisk JD et al (1994) Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clin Infect Dis 18(Suppl 1):S79-83","journal-title":"Clin Infect Dis"},{"issue":"6","key":"11134_CR52","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","volume":"67","author":"AS Zigmond","year":"1983","unstructured":"Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67(6):361\u2013370","journal-title":"Acta Psychiatr Scand"},{"issue":"7","key":"11134_CR53","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1177\/1545968314521010","volume":"28","author":"I Baert","year":"2014","unstructured":"Baert I et al (2014) Responsiveness and clinically meaningful improvement, according to disability level, of five walking measures after rehabilitation in multiple sclerosis: a European multicenter study. Neurorehabil Neural Repair 28(7):621\u2013631","journal-title":"Neurorehabil Neural Repair"},{"issue":"5","key":"11134_CR54","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1177\/1352458517690821","volume":"23","author":"RH Benedict","year":"2017","unstructured":"Benedict RH et al (2017) Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis. Mult Scler 23(5):721\u2013733","journal-title":"Mult Scler"},{"issue":"4","key":"11134_CR55","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1177\/135245850100700409","volume":"7","author":"JB Boringa","year":"2001","unstructured":"Boringa JB et al (2001) The brief repeatable battery of neuropsychological tests: normative values allow application in multiple sclerosis clinical practice. Mult Scler 7(4):263\u2013267","journal-title":"Mult Scler"},{"issue":"6","key":"11134_CR56","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1191\/1352458502ms839oa","volume":"8","author":"P Flachenecker","year":"2002","unstructured":"Flachenecker P et al (2002) Fatigue in multiple sclerosis: a comparison of different rating scales and correlation to clinical parameters. Mult Scler 8(6):523\u2013526","journal-title":"Mult Scler"},{"issue":"2","key":"11134_CR57","doi-asserted-by":"publisher","DOI":"10.2196\/resprot.3098","volume":"3","author":"RE Boeschoten","year":"2014","unstructured":"Boeschoten RE et al (2014) A computer-based screening method for distress in patients with multiple sclerosis: a feasibility study. JMIR Res Protoc 3(2):e29","journal-title":"JMIR Res Protoc"},{"key":"11134_CR58","doi-asserted-by":"publisher","first-page":"135245852110032","DOI":"10.1177\/13524585211003291","volume":"27","author":"A Theodorsdottir","year":"2021","unstructured":"Theodorsdottir A et al (2021) Alemtuzumab treatment in Denmark: a national study based on the Danish Multiple Sclerosis Registry. Mult Scler 27:13524585211003292","journal-title":"Mult Scler"},{"issue":"8","key":"11134_CR59","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.2522\/ptj.20120479","volume":"93","author":"RW Motl","year":"2013","unstructured":"Motl RW, McAuley E, Sandroff BM (2013) Longitudinal change in physical activity and its correlates in relapsing-remitting multiple sclerosis. Phys Ther 93(8):1037\u20131048","journal-title":"Phys Ther"},{"issue":"2","key":"11134_CR60","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s001980200001","volume":"13","author":"L Warming","year":"2002","unstructured":"Warming L, Hassager C, Christiansen C (2002) Changes in bone mineral density with age in men and women: a longitudinal study. Osteoporos Int 13(2):105\u2013112","journal-title":"Osteoporos Int"},{"issue":"8","key":"11134_CR61","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s40263-014-0173-3","volume":"28","author":"S Gupta","year":"2014","unstructured":"Gupta S et al (2014) Osteoporosis and multiple sclerosis: risk factors, pathophysiology, and therapeutic interventions. CNS Drugs 28(8):731\u2013742","journal-title":"CNS Drugs"},{"issue":"2","key":"11134_CR62","doi-asserted-by":"publisher","first-page":"176","DOI":"10.2522\/ptj.20070064","volume":"88","author":"J Paltamaa","year":"2008","unstructured":"Paltamaa J et al (2008) Measuring deterioration in international classification of functioning domains of people with multiple sclerosis who are ambulatory. Phys Ther 88(2):176\u2013190","journal-title":"Phys Ther"},{"doi-asserted-by":"crossref","unstructured":"Taul-Madsen L et al (2021) Is aerobic or resistance training the most effective exercise modality for improving lower extremity physical function and perceived fatigue in people with multiple sclerosis? A systematic review and meta-analysis. Arch Phys Med Rehabilit (In Press)","key":"11134_CR63","DOI":"10.1016\/j.apmr.2021.03.026"},{"key":"11134_CR64","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/ane.13289","volume":"142","author":"S Mamoei","year":"2020","unstructured":"Mamoei S et al (2020) Neurophysiological impairments in multiple sclerosis-Central and peripheral motor pathways. Acta Neurol Scand 142:401\u2013417","journal-title":"Acta Neurol Scand"},{"key":"11134_CR65","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.jns.2017.03.022","volume":"376","author":"M Jorgensen","year":"2017","unstructured":"Jorgensen M et al (2017) Muscle strength and power in persons with multiple sclerosis\u2014a systematic review and meta-analysis. J Neurol Sci 376:225\u2013241","journal-title":"J Neurol Sci"},{"issue":"2","key":"11134_CR66","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.rehab.2019.11.005","volume":"63","author":"C Ramari","year":"2020","unstructured":"Ramari C et al (2020) The importance of lower-extremity muscle strength for lower-limb functional capacity in multiple sclerosis: systematic review. Ann Phys Rehabil Med 63(2):123\u2013137","journal-title":"Ann Phys Rehabil Med"},{"issue":"1","key":"11134_CR67","doi-asserted-by":"publisher","first-page":"4984","DOI":"10.1038\/s41598-018-22676-0","volume":"8","author":"L Filli","year":"2018","unstructured":"Filli L et al (2018) Profiling walking dysfunction in multiple sclerosis: characterisation, classification and progression over time. Sci Rep 8(1):4984","journal-title":"Sci Rep"},{"issue":"8","key":"11134_CR68","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1177\/1352458511403641","volume":"17","author":"JC Kempen","year":"2011","unstructured":"Kempen JC et al (2011) Community walking can be assessed using a 10-metre timed walk test. Mult Scler 17(8):980\u2013990","journal-title":"Mult Scler"},{"issue":"1","key":"11134_CR69","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00415-017-8676-8","volume":"265","author":"D Conradsson","year":"2018","unstructured":"Conradsson D et al (2018) Changes in disability in people with multiple sclerosis: a 10-year prospective study. J Neurol 265(1):119\u2013126","journal-title":"J Neurol"},{"issue":"21","key":"11134_CR70","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1212\/01.wnl.0000436065.97642.d2","volume":"81","author":"MD Goldman","year":"2013","unstructured":"Goldman MD et al (2013) Clinically meaningful performance benchmarks in MS: timed 25-foot walk and the real world. Neurology 81(21):1856\u20131863","journal-title":"Neurology"},{"issue":"4","key":"11134_CR71","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1177\/1352458520913439","volume":"27","author":"BC Healy","year":"2021","unstructured":"Healy BC et al (2021) Trajectories of Symbol Digit Modalities Test performance in individuals with multiple sclerosis. Mult Scler 27(4):593\u2013602","journal-title":"Mult Scler"},{"issue":"2","key":"11134_CR72","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1177\/1352458507081274","volume":"14","author":"L Costelloe","year":"2008","unstructured":"Costelloe L et al (2008) The longitudinal relationship between the patient-reported Multiple Sclerosis Impact Scale and the clinician-assessed Multiple Sclerosis Functional Composite. Mult Scler 14(2):255\u2013258","journal-title":"Mult Scler"},{"issue":"12","key":"11134_CR73","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1177\/1352458514529173","volume":"20","author":"JM Sonder","year":"2014","unstructured":"Sonder JM et al (2014) Do patient and proxy agree? Long-term changes in multiple sclerosis physical impact and walking ability on patient-reported outcome scales. Mult Scler 20(12):1616\u20131623","journal-title":"Mult Scler"},{"key":"11134_CR74","first-page":"205521731559699","volume":"1","author":"L Mehta","year":"2015","unstructured":"Mehta L et al (2015) Identifying an important change estimate for the Multiple Sclerosis Walking Scale-12 (MSWS-12v1) for interpreting clinical trial results. Mult Scler J Exp Transl Clin 1:2055217315596993","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"11","key":"11134_CR75","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1007\/s00415-006-0247-3","volume":"253","author":"N T\u00e9llez","year":"2006","unstructured":"T\u00e9llez N et al (2006) Fatigue in multiple sclerosis persists over time: a longitudinal study. J Neurol 253(11):1466\u20131470","journal-title":"J Neurol"},{"issue":"Pt 1","key":"11134_CR76","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1348\/147608308X345614","volume":"82","author":"RF Brown","year":"2009","unstructured":"Brown RF et al (2009) Longitudinal assessment of anxiety, depression, and fatigue in people with multiple sclerosis. Psychol Psychother 82(Pt 1):41\u201356","journal-title":"Psychol Psychother"},{"key":"11134_CR77","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.msard.2019.07.028","volume":"35","author":"S Rooney","year":"2019","unstructured":"Rooney S et al (2019) Minimally important difference of the fatigue severity scale and modified fatigue impact scale in people with multiple sclerosis. Mult Scler Relat Disord 35:158\u2013163","journal-title":"Mult Scler Relat Disord"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-022-11134-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-022-11134-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-022-11134-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T16:10:48Z","timestamp":1660061448000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-022-11134-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,28]]},"references-count":77,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["11134"],"URL":"https:\/\/doi.org\/10.1007\/s00415-022-11134-7","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"type":"print","value":"0340-5354"},{"type":"electronic","value":"1432-1459"}],"subject":[],"published":{"date-parts":[[2022,4,28]]},"assertion":[{"value":"18 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and\/or publication of this article: Lars G. Hvid has received travel grants and\/or teaching honorary from Biogen and Sanofi Genzyme; Egon Stenager ES declare no conflict of interests; Ulrik Dalgas has received research support, travel grants and\/or teaching honorary from Biogen, Merck Serono, Novartis, Bayer Schering and Sanofi Aventis as well as honoraria from serving on scientific meetings of Biogen and Sanofi Genzyme.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study was conducted in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments, and was approved by the ethics committee of the central Denmark region (record 1-10-72-223-16).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}